Skip to main content

Insulin aspart

04-29-2022 | ATTD 2022 | Conference coverage | News

Concentrated rapid-acting insulin shows early promise

Results of a phase 1 study show that a concentrated version of insulin aspart not only provides a smaller injection volume but also has a more rapid onset of action than the standard version.

06-28-2021 | ADA 2021 | Conference coverage | News

Pramlintide, prandial insulin co-formulation gives benefits of both in one injection

A co-formulation of pramlintide and a prandial insulin offers improved postprandial glucose control and weight loss, without an increased number of injections, show the results of a small crossover trial.

05-07-2020 | Insulin aspart | News

Insulin aspart biosimilar gets EMA nod

Click through to read more on this announcement

03-31-2020 | Faster-acting insulin aspart | News

Onset 9: Faster aspart may have advantages over insulin aspart in advanced type 2 diabetes

Fast-acting insulin aspart results in equal, but not better, glycemic control to insulin aspart in adults whose long-standing type 2 diabetes is not adequately controlled with a basal–bolus regimen, a trial conducted in 17 countries suggests.

08-13-2018 | Insulin degludec | News

Fixed degludec–aspart co-formulation shows promise in pediatric diabetes

The fixed soluble co-formulation of insulin degludec/insulin aspart offers similar glycemic control to insulin detemir when each are combined with mealtime insulin aspart in children with type 1 diabetes, research shows.

09-20-2017 | Hypoglycemia | EASD 2017 | News

Hypoglycemia: Risk factors and Ramadan

Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

04-05-2017 | Insulin aspart | News

Fast-acting insulin aspart offers promising glycemic control

Results of the Onset 1 trial confirm that treatment with fast-acting insulin aspart provides improves glycemic control compared with conventional insulin aspart among adults with type 1 diabetes.

02-10-2017 | Faster-acting insulin aspart | News

Ultrafast-acting insulin effective in children

The pharmacodynamics of faster-acting insulin aspart in children are similar to those in adults, suggesting its ability to improve postprandial glycemic control in children with type 1 diabetes, say researchers.

Related topics